Market Overview

UPDATE: Piper Jaffray Raises PT to $9 on Rigel Pharmaceuticals Ahead of Fostamatinib Readout

Related RIGL
Benzinga's Top Upgrades, Downgrades For December 15, 2017
Benzinga's Top Upgrades, Downgrades For November 6, 2017

Piper Jaffray maintained Rigel Pharmaceuticals (NASDAQ: RIGL) with an Overweight rating and raised the price target from $8.00 to $9.00.

Piper Jaffray commented, "While shares have been volatile following OSKIRA-4, we continue to believe fostamatinib is an approvable drug. Bears can point to fostamatinib's failure to achieve non-inferiority compared to Humira, however we note that the Humira ACR20 score of 59% was well above what was seen in the tofacitinib trial (36%), with management commentary suggesting fostamatinib's score approached that of Humira. In addition, we note that no new safety signals emerged. We believe fostamatinib's near miss on efficacy, combined with potential to demonstrate radiographic benefit in Phase III, provide an opportunity for shares to recover."

Rigel Pharmaceuticals closed at $6.82 on Monday.

Latest Ratings for RIGL

Dec 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Nov 2017H.C. WainwrightAssumesBuyBuy
Sep 2016JefferiesMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (RIGL)

View Comments and Join the Discussion!